Diabetes Pro Quarterly - Summer 2019 - 18

RESEARCH NEWS
Scientific & Health Care Achievement Award Recipients continued from page 17
Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results) trial,
which was the first demonstration of the
broad effect of the glucagon-like peptide
1 receptor agonist liraglutide in reducing
cardiovascular events and mortality in
patients with type 2 diabetes and high cardiovascular risk. Dr. Buse has been listed
since 2015 among Thompson Reuters
"highly cited researchers," which recognizes the top 1% of global investigators.
He is widely sought after as a lecturer,
consultant, collaborator, and clinical trial
investigator.

Outstanding Educator in
Diabetes Award
Virginia Valentine,
APRN-CNS, BC-ADM,
CDE, FAADE
Ms. Valentine is a
diabetes specialist with
Clinica La Esperanza in
Alburquerque, NM, where she manages
a wide variety of diabetes clinical care
challenges in a primary care practice.
She holds faculty appointments with the
University of New Mexico and serves as
clinician faculty for the Endocrinology
TeleECHO Clinic, which trains and
supports primary care providers in rural
and underserved communities to improve
their knowledge of and skill in providing
endocrinological care. Ms. Valentine has
provided professional education on a
state, national, and international level. Her
delivery always includes audience participation and instills a sense of confidence
and willingness to try something new.
Her contributions have been recognized
by the Distinguished Service Award from
the American Association of Diabetes
Educators (AADE), an organization in
which she is a fellow. Ms. Valentine is
also a member of the Advanced Practice
Advisory Board for the New Mexico
Board of Nursing. She has served on the

editorial board for Clinical Diabetes and is
currently an editorial board member for
the Canadian Journal of Diabetes and an
advisory board member for diaTribe. In
addition to journal articles, Ms. Valentine
authored the book Diabetes: The New Type
2 and contributed to The Art and Science
of Diabetes Self-Management Education
Desk Reference and the third edition of the
Complete Nurse's Guide to Diabetes Care.

Outstanding Physician Clinician in
Diabetes Award
David C. Klonoff, MD
Dr. Klonoff is the medical
director of the Diabetes
Research Institute at
Mills-Peninsula Medical
Center and a clinical
professor of medicine at the University
of California, San Francisco. He practices endocrinology in Burlingame,
CA. In 1998, Dr. Klonoff coined the term
"diabetes technology" when the focus of
diabetes treatment was on biology. He
has been a leader in diabetes hardware,
software, digital health, and device cybersecurity and received an U.S. Food and
Drug Administration Director's Special
Citation Award for his work in diabetes
technology. In 2000, he founded the
Diabetes Technology Society, a nonprofit
organization promoting the development
and use of technology for patients with
diabetes. Dr. Klonoff has spoken to the
U.S. Congressional Diabetes Caucus, participated in the White House Health and
Cybersecurity Roundtable, and spoken
at the European Parliament. He has been
a principal investigator in more than 110
clinical trials of devices and drugs and
has published more than 200 articles in
PubMed-indexed journals. Dr. Klonoff
is also the founding editor-in-chief
of the Journal of Diabetes Science and
Technology. He has chaired three diabetes
device cybersecurity standard steering

Important Deadlines for ADA-Funded Research Awards

18

Final progress report (cumulative scientific and financial)
for Core awards with a June 30, 2019, end date

September 2, 2019

Final progress report (cumulative scientific and financial)
for Targeted awards with an August 31, 2019, end date

November 1, 2019

Scientific progress reports for Core and Pathway award
holders with a January 1 start date

November 1, 2019

committees, the Diabetes Technology
Society Surveillance Program for Cleared
Blood Glucose Monitors, the Endocrine
Society Continuous Glucose Monitoring
(CGM) Clinical Guidelines Committee,
and the Clinical & Laboratory Standards
Institute CGM Performance Metrics
Committee.

Albert Renold Award
Rudolf L. Leibel, MD
Dr. Leibel is the recipient of the 2019 Albert
Renold Award, which is
presented to an individual whose career is
distinguished by outstanding achievements in the training and mentorship
of diabetes research scientists and in the
development of communities of scientists
to enhance diabetes research. Dr. Leibel
is the Christopher J. Murphy Memorial
Professor of Diabetes Research, a professor
of pediatrics and medicine, head of the
Division of Molecular Genetics, and
co-director of the Naomi Berrie Diabetes
Center at Columbia University. He and his
associates have carefully crafted a scientific
environment in which the curiosity of students and fellows is encouraged. To enable
these efforts, he successfully lobbied the
Russell Berrie Foundation to establish the
Naomi Berrie Fellowship and the Russell
Berrie Scholar Programs, each of which
support postdoctoral scientists in training
at Columbia University and throughout
the world. Dr. Leibel has continued to chair
the program and has overseen awards to
more than 50 Berrie Fellows and Scholars
over the past 20 years. He has trained more
than 60 graduate students and postdoctoral
fellows in research related to the molecular pathogenesis of obesity and diabetes.
Dr. Leibel's basic research and clinical
investigations have helped to define key
molecular components of the regulatory
system that controls body weight and
adiposity, the inflammatory response to
obesity, and genetic susceptibility to type 2
diabetes. Most recently, he and his collaborators have used stem cell-based strategies
to create and analyze human islet and
hypothalamic cells as experimental tools in
the analysis of the molecular physiology of
diabetes and obesity.
continued on page 19
Diabetes Pro Quarterly - Summer 2019

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Summer 2019
